- Home
- HRMY vs VYX Comparison
HRMY vs VYX Comparison
Compare HRMY & VYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRMY
- VYX
- Stock Information
- Founded
- HRMY 2017
- VYX 1881
- Country
- HRMY United States
- VYX United States
- Employees
- HRMY N/A
- VYX N/A
- Industry
- HRMY Biotechnology: Pharmaceutical Preparations
- VYX
- Sector
- HRMY Health Care
- VYX
- Exchange
- HRMY Nasdaq
- VYX Nasdaq
- Market Cap
- HRMY 1.8B
- VYX 1.5B
- IPO Year
- HRMY 2020
- VYX N/A
- Fundamental
- Price
- HRMY $34.00
- VYX $13.41
- Analyst Decision
- HRMY Strong Buy
- VYX Strong Buy
- Analyst Count
- HRMY 9
- VYX 5
- Target Price
- HRMY $54.44
- VYX $14.40
- AVG Volume (30 Days)
- HRMY 642.5K
- VYX 1.8M
- Earning Date
- HRMY 08-05-2025
- VYX 08-05-2025
- Dividend Yield
- HRMY N/A
- VYX N/A
- EPS Growth
- HRMY 13.13
- VYX N/A
- EPS
- HRMY 2.62
- VYX 6.72
- Revenue
- HRMY $744,852,000.00
- VYX $2,733,000,000.00
- Revenue This Year
- HRMY $20.10
- VYX N/A
- Revenue Next Year
- HRMY $18.01
- VYX N/A
- P/E Ratio
- HRMY $13.10
- VYX $1.98
- Revenue Growth
- HRMY 20.62
- VYX N/A
- 52 Week Low
- HRMY $26.47
- VYX $7.55
- 52 Week High
- HRMY $41.61
- VYX $15.34
- Technical
- Relative Strength Index (RSI)
- HRMY 58.91
- VYX 74.11
- Support Level
- HRMY $31.70
- VYX $13.12
- Resistance Level
- HRMY $35.08
- VYX $13.67
- Average True Range (ATR)
- HRMY 0.95
- VYX 0.45
- MACD
- HRMY 0.27
- VYX 0.10
- Stochastic Oscillator
- HRMY 71.80
- VYX 79.81
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About VYX NCR Voyix Corporation
NCR Voyix Corp is a company providing services of digital commerce solutions for retail, restaurant, and digital banking. The company operates in three reportable segments: Retail, Restaurants, and Digital Banking. The Retail segment provides software solutions for retailers of all sizes, enhancing operational efficiency and customer experience. The Restaurants segment offers end-to-end technology solutions for food service establishments, improving operational efficiency, and customer satisfaction, and reducing costs. The Digital Banking segment serves financial institutions with cloud-based software solutions for a fully integrated digital banking experience across channels. Revenue sources include software sales and service support within each segment.